Dr Gordon has been a senior drug discovery executive, venture capital investor, science-stage biotech consultant, and an adjunct Stanford professor, with 40 years of experience in the pharmaceutical industry (18 years), biotech startup companies (10 years), venture investing (11 years), and academia (4 years). Eric Gordon has had close involvement in the discovery/development of 11 approved drugs and have participated in the founding/co-founding 5 companies. My scientific background lies in bioorganic/medicinal chemistry, specifically in the rational design of enzyme inhibitors, combinatorial chemistry, anti-infective chemistry, and the organic chemistry of amino acids, peptides, proteins, post-translational modification of peptides and proteins, phosphorous containing molecules, beta-lactam antibiotics, and natural product chemistry,

Peter S. Kim is the Virginia & D.K. Ludwig Professor of Biochemistry at Stanford University School of Medicine and an Institute Scholar of Stanford ChEM-H. He is also a Senior Investigator of the Infectious Disease Initiative at the Chan Zuckerberg Biohub. He was President of Merck Research Laboratories from 2003–2013 and oversaw the development of more than 20 new medicines and vaccines, including JANUVIA, GARDASIL, ISENTRESS, ZOSTAVAX, and KEYTRUDA. Earlier, he was a Professor of Biology at MIT, a Member of the Whitehead Institute, and an HHMI Investigator. He is known for discovering a salient component of how proteins cause viral membranes to fuse with cells and has pioneered efforts to create an AIDS vaccine based on inhibiting the HIV-1 membrane-fusion process. He is a member of the National Academy of Sciences, the National Academy of Medicine, and the National Academy of Engineering

Nancy Chang, Ph.D., is the Chairperson of the Board, and has served as a Director of Ansun since 2011. Nancy was the Chairperson and Senior Managing Director of Caduceus Asia Partners at OrbiMed Advisors from 2007 to 2012. From 1987 to 2007, Dr. Chang served as Co-Founder, President and Chairman of Tanox, Inc., which was acquired by Genentech in 2007. Prior to founding Tanox, Dr. Chang held several leadership positions at Centocor, now a division of Johnson & Johnson. She was also an Associate Professor at Baylor College of Medicine. She has served on the board of several companies, including SciClone Pharmaceuticals, Inc., Charles River Laboratories International, Inc., and Inspirna, Inc. Nancy received her Doctorate in Biological Chemistry from Harvard University.

Dr Gordon has been a senior drug discovery executive, venture capital investor, science-stage biotech consultant, and an adjunct Stanford professor, with 40 years of experience in the pharmaceutical industry (18 years), biotech startup companies (10 years), venture investing (11 years), and academia (4 years). Eric Gordon has had close involvement in the discovery/development of 11 approved drugs and have participated in the founding/co-founding 5 companies. My scientific background lies in bioorganic/medicinal chemistry, specifically in the rational design of enzyme inhibitors, combinatorial chemistry, anti-infective chemistry, and the organic chemistry of amino acids, peptides, proteins, post-translational modification of peptides and proteins, phosphorous containing molecules, beta-lactam antibiotics, and natural product chemistry,

Dr. Exon is a Pharmaceutical R&D consultant with over 30 years’ experience in the scale-up of small molecule manufacturing processes, from the laboratory to the pilot-plant, process research, early chemical development regulatory requirements and synthetic organic chemistry. He has a broad background in global drug development. He has demonstrated outstanding ability to work in a global environment with consistent record of effectively engaging and managing cross functional groups to accomplish company goals. His specialties include API (Drug Substance) Supply; Process Research and Process Development; Pilot Plant Operations; Regulatory Compliance (GMP, EH&S); Regulatory Submissions (INDs); Document Generation & Review; Facility (Pilot Plant, Lab.) Construction, Commissioning/Qualification and Decommisioning; and Department/Project Leadership/Management.

Dr. Narmada Shenoy has been involved in the strategy, design and execution of multi-disciplinary programs spanning CMCand non-clinical development in the pharmaceutical industry, for over 25 years. While at SUGEN Inc. (acquired by Pharmacia/Pfizer), she led a team to enable accelerated development of multiple NCEs from the laboratory through clinical trials, using novel formulation strategies, including development of FDA approvedoncology products, SUTENT® and PALLADIA®. As both an independent Chemistry Manufacturing and Controls (CMC) consultant at ENNARS Associates and in her current role as CEO of AraVasc Inc., she has worked with multiple clients for stage-appropriate pharmaceutical development, from pre-IND to NDA stage, leading multi-disciplinary teams focused on CMC and non-clinical development. More recently, she led a CMC and a non-clinical development team towards an accelerated filing of an Investigational Medicinal Product Dossier (IMPD) and Investigational New Drug (IND) application with the European and US regulatory agencies, to enable clinical trials of a novel product for cancer patients. She has a background in pharmaceutical drug development is a trained chemist with a track record for applying it to develop novel formulations and characterization methods to solve delivery challenges.​

Dr. Alden, former Vice President for Drug Safety Evaluation at Takeda Pharmaceuticals, Inc., has the responsibility for developing and executing the safety assessment strategy to enable generation of the vast information sufficient to successfully enter clinical testing and register drugs across multiple therapeutic categories.

He previously served as Editor, Veterinary Pathology; Board of Directors of the Aspen Cancer Conference; Editor, Toxicologic Pathology; Board of Directors of the American Registry of Pathology; President, Society of Toxicologic Pathologists; and Council on Research of the American Veterinary Medical Association. He played a leadership role in the international effort leading to approved alternatives to the life time mouse cancer bioassay.

Dr McClure is a drug development consultant with extensive experience in pharmaceutical drug development, clinical research, regulatory affairs and quality assurance. Over the past 35 years, she has worked with on multiple drug development programs, covering new chemical entities as well as repositioning and enhancing older drug products to meet new clinical challenges. She has filed more than 50 INDs/CTAs and several NDA/MAAs for clinical trials in the US, Canada, Western Europe, Eastern Europe, Russia, India, and China. Dr. McClure obtained her PhD in Organic Chemistry from Stanford University in 1979 and BS in Chemistry from the University of Michigan in 1974.